<DOC>
	<DOCNO>NCT02747654</DOCNO>
	<brief_summary>Isoniazid ( INH ) essential component first-line anti-tuberculosis ( TB ) treatment . However , treatment INH complicate polymorphisms expression enzyme system primarily responsible elimination , N-acetyltransferase 2 ( NAT2 ) , associate hepatotoxicity . The objective study develop individualized INH dose regimen use pharmacogenetic-driven model apply regimen pilot study .</brief_summary>
	<brief_title>Isoniazid Dosage Prediction Model Development</brief_title>
	<detailed_description />
	<criteria>Eligible participant patient newly diagnose active TB Who undergo standard four drug treatment 6months : isoniazid ( 5 mg/kg , usually 300 mg ) , rifampin ( 450 mg &lt; 50 kg 600 mg 50 kg body weight ) , ethambutol ( 15mg/kg ) , pyrazinamide ( 20 30 mg/kg ) Given daily two month follow isoniazid rifampin without ethambutol four month . Those patient abnormal hepatic function laboratory test ( increase serum aspartate aminotransferase , alanine aminotransferase , total bilirubin ) antiTB treatment , underlie liver disease systemic illness congestive heart failure , acute lifethreatening disease , alcoholism , disease resistant INH start treatment exclude .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>NAT2 genotype guide dosing</keyword>
</DOC>